ClinicalTrials.gg
CompletedNCT03079050Updated Sep 15, 2017

An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan

A Phase 4 interventional study of Dexlansoprazole 60 MG in GERD and Proton Pump Inhibitor, sponsored by American University of Beirut Medical Center. Completed at 1 site in Lebanon. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-15.

Sponsored by American University of Beirut Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2017, 9 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing dexlansoprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Dexlansoprazole · Gastroesophageal Reflux.

Enrollment
20th of 27
33 · median 104
Started
2017
with 2 others
Phase 4
6 of 27
none open now
Registered
23rd of 27
by date
Lead sponsor
1 of 27
American University of Beirut Medical Center

Among the 27 studies testing dexlansoprazole in Gastroesophageal Reflux, this one is the 20th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 4, and was the 23rd registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 27 studies testing dexlansoprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About dexlansoprazole

Dexlansoprazole: first FDA approval 2009 (DEXILANT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing dexlansoprazole in Gastroesophageal Reflux as a file.
02

Study summary

Dexlansoprazole modified release (MR), the R-enantiomer of Lansoprazole, is an FDA approved drug (2009) for the management of erosive esophagitis and nonerosive reflux disease 1. Dexlansoprazole has a unique dual delayed-release delivery system designed to address unmet needs that may accompany traditional proton pump inhibitors, with two separate pH-depended release phases, the first in the proximal duodenum and the second in the more distal small intestine. This dual release system extends the plasma concentration and pharmacodynamics effects beyond those of single-release PPIs, allowing for dosing at any time of the day without regard to meals 1. A study conducted by Fass et al. has shown that the use of dexlansoprazole MR 30 mg in patients with symptomatic GERD is significantly more effective than placebo in improving nocturnal heartburn, reducing GERD-related sleep disturbances, and consequently improving work productivity, sleep quality and quality of life 2.

Because of its pharmacokinetic properties, Dexlansoprazole modified release (MR) may prove beneficial in optimizing the management of GERD and the associated burdens that often surface after the heavy evening and Suhur meals, such as increased nocturnal symptoms and poor sleep quality.

Read the detailed description

To investigate the efficacy and quality of life improvement of Dexlansoprazole 60mg taken once daily at Iftar time in patients with known symptomatic heartburn exacerbated in Ramadan and who are not on daily treatment.

03

Conditions studied

  • GERD
  • Proton Pump Inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 18-75 years old
  • Fasting in Ramadan
  • No daily PPI use
  • Individuals willing to sign consent form
  • Patients owning a smartphone and able to use a smartphone application

Exclusion criteria

Exclusion Criteria:

  • Known erosive GERD on PPI
  • Pregnant females
  • Prior gastric surgery
  • Long standing diabetes mellitus (≥10 years of disease)
  • Frequent NSAID use (>3x/week)
  • Morbid obesity (>35)
  • History of recent (\<6 months) upper GI bleeding
  • Patients who do not own a smartphone or who cannot use a smartphone application
  • Known allergy to PPIs
  • Known history of poor compliance or adherence and active psychological problems which might impact adherence
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    1

    34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.

    Drug: Dexlansoprazole 60 MG

Interventions

  • DrugDexlansoprazoleStudies of DexlansoprazoleDexlansoprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms

    Also known as: Dexilant 60 MG

06

What researchers measure

Primary outcomes

  1. Heartburn Relief

    The mean number of days during Ramadan with complete relief of heartburn symptoms, including nocturnal symptoms.

    Time frame: 1 month

Secondary outcomes

  1. Days with partial relief of heartburn symptoms

    Days with partial relief of heartburn symptoms

    Time frame: 1 month

  2. Days with relief of nocturnal heartburn symptoms

    Days with relief of nocturnal heartburn symptoms

    Time frame: 1 month

  3. Improvement in sleep qualit

    The number of nocturnal sleeping hours will be assessed daily

    Time frame: 1 month

  4. Side effects/tolerability of Dexlansoprazole 30mg vs. Dexlansoprazole 60mg

    "Side effects and tolerability" Questionnaire

    Time frame: 1 month

07

Study locations

1 site
  • American University of Beirut - Medical Center
    Beirut, Lebanon
08

References and documents

Publications

  • Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45. doi: 10.1586/egh.11.37. PubMed 21780890 ↗
  • Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, Pilmer BL, Perez MC. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011 Mar;106(3):421-31. doi: 10.1038/ajg.2010.458. Epub 2011 Jan 11. PubMed 21224838 ↗
  • Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53. doi: 10.1016/j.cgh.2011.11.021. Epub 2011 Dec 7. PubMed 22155561 ↗
  • Solem C, Mody R, Stephens J, Macahilig C, Gao X. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence. J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):144-53. doi: 10.1331/JAPhA.2014.13117. PubMed 24632930 ↗
  • Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV; American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008 Oct;135(4):1383-1391, 1391.e1-5. doi: 10.1053/j.gastro.2008.08.045. No abstract available. PubMed 18789939 ↗
  • Abbas Z. Gastrointestinal health in Ramadan with special reference to diabetes. J Pak Med Assoc. 2015 May;65(5 Suppl 1):S68-71. PubMed 26013794 ↗
  • Rimmani HH, Rustom LBO, Rahal MA, Shayto RH, Chaar H, Sharara AI. Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan. Dig Dis. 2019;37(3):188-193. doi: 10.1159/000496091. Epub 2019 Jan 9. PubMed 30625462 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jul 2017, 5 months.

Of 30 phase 4 interventional studies under Gastroesophageal Reflux, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2017
First posted
Mar 14, 2017
StartActual
Feb 27, 2017
Primary completionActual
Jul 30, 2017
CompletionActual
Jul 30, 2017
Last update
Sep 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03079050
Collaborators
Takeda
Responsible party
Sponsor
First posted
Mar 14, 2017
Start date
Feb 27, 2017
Primary completion
Jul 30, 2017
Completion
Jul 30, 2017
Last update
Sep 15, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexlansoprazole

Start the discussion